跳至主要内容
临床试验/IRCT201501059979N2
IRCT201501059979N2已完成2 期

Study of efficacy and safety of low-dose rate endorectal brachytherapy in patients with clinical stage T2N1 or T3-4N0-2 resectable low rectal cancer

Vice chancellor for research,, Shiraz University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 90 years(—)
性别
All

入选标准

  • Inclusion Criteria:
  • Pathologically proved adenocarcinoma of the rectum
  • Age 18 or older
  • Clinically staged II-III tumor by MRI and/or EUS
  • ECOG performance status of 0 or 1
  • Tumors located at up to10 cm of the anus
  • No previous history of malignancy, pelvic radiotherapy or chemotherapy
  • Normal or adequate bone marrow reserve
  • Normal or adequate liver and kidney function

排除标准

  • Patients with tumors >12 cm from the anal verge.
  • Near obstructing or bulky tumors which will not allow application of the endorectal applicator before or after chemoradiation
  • Patients with distant metastatic disease
  • Prior history of radiation therapy to the pelvis
  • Prior history of chemotherapy for rectal cancer
  • Active connective tissue disease such as scleroderma or Crohn's disease
  • Uncontrolled diabetes mellitus, hypertension or recent cardiovascular disease
  • Significant neuropathy
  • Any previous or recent hypersensitivity or contraindication for chemotherapy agents

研究者

发起方
Vice chancellor for research,, Shiraz University of Medical Sciences

相似试验